HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...
2d
Zacks Investment Research on MSNPTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis StudyProtagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated ...
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
3d
GlobalData on MSNJ&J and Protagonist’s icotrokinra scores in Phase IIb UC studyGlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
JNJ's ulcerative colitis drug shows promise in mid-stage trials, with high response rates and well-tolerated safety profile ...
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical response in all icotrokinra dose groups evaluated and demonstrated clinically ...
highlighted icotrokinra’s potential to change the treatment landscape for UC, citing its combination of efficacy, tolerability, and convenient once-daily oral dosing. Ulcerative colitis is a ...
H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $80 from $54 and keeps a Buy rating on the shares. The ...
Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra ... to severely active ulcerative colitis (UC), a chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results